Company Analysis

Entera Bio Ltd. (ENTX)

Nasdaq: ENTX · Biological Products, (No Diagnostic Substances) · Jerusalem · filing with the SEC since 2015
Grade3.9
◀ Past 3.4● Present 3.5▶ Future 4.5
1 est.

Who runs Entera Bio Ltd.

Officers and directors as they report to the SEC on Forms 3, 4 and 5, named as filed
Chief executive, as filed
Toledano Miranda Jayne
Chief Executive Officer. First filing Jan 2022, latest Aug 7, 2026, 5 filings in all.
Officers reporting now
5
of 12 people with a filing in the last fifteen months
Directors reporting now
7
19 people on the record since 2022
Officerssales are open-market, Sep 30, 2025 to Sep 30, 2026
NameTitle as filedFirst filingLatest filingSales, 12 months
Camisasca Riccardo PaoloChief Medical OfficerAug 2026Aug 21, 2026none
Toledano Miranda JayneChief Executive OfficerJan 2022Aug 7, 2026none
Yaacov-Garbeli DanaChief Financial OfficerFeb 2022Aug 7, 2026none
Galitzer HillelChief Operating OfficerJan 2022Aug 7, 2026none
Burshtein GregoryChief of R&DJun 2024Aug 7, 2026none
Directorssales are open-market, Sep 30, 2025 to Sep 30, 2026
NameRoleFirst filingLatest filingSales, 12 months
Ellis SeandirectorJan 2022Aug 7, 2026none
Germano Geno JdirectorFeb 2026Aug 7, 2026none
Malca YonatandirectorJan 2022Aug 7, 2026none
Rubin Steven DdirectorFeb 2026Aug 7, 2026none
Taitel HayadirectorAug 2023Aug 7, 2026none
Lieberman Gerald MdirectorJan 2022Jan 2, 2026none
Ostrov Gerald MdirectorJan 2022Jan 2, 2026none
Earlier names on the record8, newest filing first

A person is listed as reporting now after a filing in the last fifteen months. The record shows when someone last filed; it does not say why they stopped. Each name links to the filings on sec.gov.

SI Assistanton ENTX · research, not advice